Latest Headlines

Latest Headlines

Mylan buys into Theravance's COPD contender in $265M deal

Generics giant Mylan is shouldering its way into the blockbuster market for COPD treatments, signing a $265 million deal with the respiratory experts at Theravance Biopharma to get its hands on a late-stage contender.

GlaxoSmithKline and Theravance eye Phase III for another COPD contender

The blockbuster duo of GlaxoSmithKline and Theravance are pushing a new respiratory combo therapy into late-stage study, pooling the active ingredients from its last two approved COPD treatments to create a once-daily inhaler.

Theravance bets it can innovate without GlaxoSmithKline as spinoff nears

Theravance, the biotech engine behind GlaxoSmithKline's bright future in COPD, is gearing up to split in two next quarter, with one publicly traded company handling its revenue-generating drugs and the other leading the charge on R&D.

Despite pomp and circumstance, 2014's looking short on blockbusters

Biopharma's long-heralded return to R&D ROI may come up short this year, according to EvaluatePharma, and the next class of approved drugs features fewer blockbusters in waiting than in any of the previous four years.

GlaxoSmithKline snags FDA approval for blockbuster COPD contender

GlaxoSmithKline and Theravance scored another victory through their profitable partnership, winning FDA approval for Anoro Ellipta, a trailblazing COPD combo therapy with billion-dollar potential.

Theravance scraps ADHD program after drug flunks PhII study

Theravance CEO Rick Winningham put out the word today that its drug TD-9855 flunked a mid-stage study for attention deficit/hyperactivity disorder, adding that the biotech planned to scrap the program while continuing a separate study for fibromyalgia.

UPDATED: FDA experts endorse new COPD blockbuster from GlaxoSmithKline, Theravance

GlaxoSmithKline and Theravance have nailed down a solid majority of FDA panel votes in favor of marketing their new COPD therapy Anoro Ellipta. The outside experts voted 11 to 2 this afternoon to endorse the therapy, opening the door to the first of several new drug that will likely wind up duking it out in a tough fight for market share.

FDA staff plugs efficacy of projected COPD blockbuster from GSK and Theravance

GlaxoSmithKline and partner Theravance are closing in on an important advisory committee meeting for their experimental lung drug Anoro Ellipta next week. And FDA staff has noted in a briefing document that the combination therapy for COPD was effective at two doses, Bloomberg reported.

Report: Theravance CEO shrugs off a soured $1B Elan deal

Elan shareholders didn't much care for Kelly Martin's $1 billion royalty deal with Theravance. Or any other deals, for that matter, aside from a share buyback. But that doesn't seem to upset Theravance CEO Rick Winningham even a little bit.

Royalty Pharma hits temporary roadblock in $6.4B bid for Elan

This round goes to Elan. In the ongoing battle for control over the Irish drugmaker, a U.S. court judge gave the company a temporary reprieve from Royalty Pharma's hostile bid of $6.4 billion, Bloomberg reported.